Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.38 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.38 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15663537 | 0.94 | NOTUM (0.48) | NOTUMBRD4MAPTGPR119TACR1 | |
| SCHEMBL6752845 | 0.85 | NOTUM (0.59) | NOTUMBRD4MAPTGPR119TACR1 | |
| SCHEMBL31064165 | 0.84 | NOTUM (0.45) | NOTUMMAPTGPR119TACR1ERAP1 | |
| SCHEMBL1452092 | 0.84 | NOTUM (0.45) | NOTUMMAPTGPR119TACR1ERAP1 | |
| SCHEMBL6341898 | 0.83 | BRD4 (0.46) | BRD4GPR119MPOKDM4E | |
| SCHEMBL26405746 | 0.83 | BRD4 (0.46) | NOTUMBRD4GPR119MPOKDM4E | |
| SCHEMBL7669258 | 0.82 | NOTUM (0.57) | NOTUMBRD4MAPTGPR119TACR1 | |
| SCHEMBL2474701 | 0.80 | BRD4 (0.39) | BRD4MAPTGPR119MPOKDM4E | |
| SCHEMBL14380662 | 0.80 | KDM1A (0.48) | NOTUMBRD4MAPTALDH1A1 | |
| SCHEMBL29960283 | 0.80 | KDM1A (0.48) | NOTUMBRD4MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749992-B2 | Compounds and methods for treating dislipidemia | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| EP-2098512-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly & Company (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-1670768-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1670768-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037796-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254869-A1 | Compounds And Methods For Treating Dislipidemia | APOB, CETP, PCSK9 | NOTUM 303/4885BRD4 2755/4885MAPT 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.